Search

Displaying results 8131 - 8140 of 10000 in total
  1. Drug

    LY-3200882

    go.drugbank.com/drugs/DB16064
    Investigational

    LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer).

  2. Drug

    Benmelstobart

    go.drugbank.com/drugs/DB17473
    Investigational

    APL 502 is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1 (PD-L1).

  3. Drug

    LY-2881835

    go.drugbank.com/drugs/DB15046
    Investigational

    LY-2881835 is under investigation in clinical trial NCT01358981 (A Study of LY2881835 in Healthy People and People With Diabetes).

  4. Drug

    Giripladib

    go.drugbank.com/drugs/DB15426
    Investigational

    Giripladib is under investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee).

  5. Drug

    Difenoxin

    go.drugbank.com/drugs/DB01501
    ApprovedIllicit

    Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. … However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse.

  6. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. … Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression

  7. Drug

    Acipimox

    go.drugbank.com/drugs/DB09055
    ApprovedInvestigational

    Acipimox is a niacin derivative used as a hypolipidemic agent. … Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL.

  8. Drug

    Epirubicin

    go.drugbank.com/drugs/DB00445
    ApprovedInvestigational

    An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.

    Synonyms: -L-ARABINO-HEXOPYRANOSIDE, -L-ARABINO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYACETYL)-1-METHOXY-, (8S-CIS)-Categories: UGT2B7 Substrates with a Narrow Therapeutic Index
  9. Drug

    Biperiden

    go.drugbank.com/drugs/DB00810
    ApprovedInvestigationalWithdrawn

    A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism.

  10. Drug

    Diflunisal

    go.drugbank.com/drugs/DB00861
    Approved

    Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs.